10 citations
,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
2 citations
,
March 2015 in “Hepatitis Monthly” A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.
6 citations
,
October 2016 in “Journal of Chemotherapy” A man lost all his hair as a rare side effect after hepatitis C treatment.
4 citations
,
August 2007 in “PubMed” A woman lost all her body hair after hepatitis C treatment, but it started to grow back a year after stopping the treatment.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
9 citations
,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
3 citations
,
March 2014 in “Annals of Hepatology” A man lost all his hair after stopping hepatitis C treatment and it didn't grow back.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
11 citations
,
April 2014 in “Journal of Clinical Virology” Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
January 2003 in “American Journal of Clinical Dermatology” Various drugs caused different skin reactions, including allergic and inflammatory responses.
2 citations
,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
32 citations
,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
21 citations
,
April 2010 in “Molecular Medicine Reports” Zinc supplementation may help improve treatment outcomes for chronic hepatitis C.
27 citations
,
August 2010 in “Clinics in Dermatology” Hepatitis C virus can cause skin diseases and dermatologists play a crucial role in identifying these conditions.
April 2021 in “Anatolian current medical journal :” A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
July 2018 in “Elsevier eBooks” Some drugs can cause reversible hair loss, but certain chemotherapy drugs may lead to permanent hair loss; drugs can also change hair color and texture.
25 citations
,
March 2019 in “Dermatologic therapy” Intralesional therapy for keratoacanthoma is effective and has fewer side effects than systemic treatments.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” Interferon and ribavirin can cause serious skin reactions and other health issues.
Compound 6 is a promising candidate for better wound healing.
52 citations
,
October 2010 in “Antiviral Therapy” New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
10 citations
,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.